

# Medical Research Council fourth non-small cell lung cancer radiotherapy study: clinical trial of radiotherapy for good-performance-status patients with inoperable non-small cell lung cancer too large in volume for radical radiotherapy

<b>Submission date</b> 19/08/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 19/08/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 15/11/2019	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr - -

**Contact details**  
UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

**Protocol serial number**  
LU13

# Study information

## Scientific Title

Medical Research Council fourth non-small cell lung cancer radiotherapy study: clinical trial of radiotherapy for good-performance-status patients with inoperable non-small cell lung cancer too large in volume for radical radiotherapy

## Study objectives

Not provided at time of registration.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration.

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Lung (non-small cell) cancer

## Interventions

1. Radiotherapy Regimen A: A total dose of 17 Gy given as two fractions of 8.5 Gy with an interval of one week between the fractions.
2. Radiotherapy Regimen B: A total dose of 39 Gy given as thirteen fractions of 3 Gy during three weeks in daily fractions five days per week.

Radiotherapy should start within two weeks of randomisation. If the patient has superior vena cava obstruction, a course of steroids may be given during the period of radiotherapy.

## Intervention Type

Other

## Phase

Not Specified

## Primary outcome(s)

Not provided at time of registration.

## Key secondary outcome(s)

Not provided at time of registration.

## Completion date

31/12/2002

## Eligibility

### Key inclusion criteria

1. Primarily untreated, microscopically confirmed non-small cell lung cancer
2. Performance status World Health Organisation (WHO) grade zero to two
3. Disease too advanced for radical radiotherapy
4. Either sex, any age

### Participant type(s)

Patient

### Healthy volunteers allowed

No

### Age group

Other

### Sex

All

### Key exclusion criteria

1. Previous surgery, radiotherapy or chemotherapy for non-small cell lung cancer
2. Other previous concomitant malignant disease. Except previous basal cell carcinoma or in situ carcinoma of the cervix
3. Evidence of distant metastases outside of the locoregional volume

### Date of first enrolment

01/01/2002

### Date of final enrolment

31/12/2002

## Locations

### Countries of recruitment

United Kingdom

England

### Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

# Sponsor information

## Organisation

Medical Research Council (MRC) (UK)

## Funder(s)

### Funder type

Research council

### Funder Name

Medical Research Council (MRC) (UK)

### Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/1994	15/11/2019	Yes	No